Rezafungin for Injection

Phase 3

Cidara Therapeutics, Inc. (CDTX)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Candidemia

View Full Landscape

Drug Information

Target Indication

Candidemia

Clinical Trial

NCT03667690

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA12/22/2023

Rezzayo

Rezzayo is indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CDTX

Cidara Therapeutics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

CD101 Vaginal Gel (3%)Phase 2

Candidiasis, Vulvovaginal

CD101Phase 2

Candidemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts